Skip to main content

PLUVICTO is the first and only PSMA-targeted radioligand therapy NOW APPROVED after only 1 ARPI1

Choose PLUVICTO: Proven in 2 large phase 3 trials and ~20K patients with PSMA+ mCRPC treated from launch to date.1-4,†

ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
*For patients considered appropriate to delay taxane-based chemotherapy.
Based on data from February 2025.

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 3. Morris MJ, Castellano D, Herrmann K, et al; PSMAfore Investigators.177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2 4. Data on file. PLUVICTO NPS Numbers. Novartis Pharmaceuticals Corp; 2025.